Catalent today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
Catalent today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
Summary: Catalent President and CEO Alessandro Maselli sits down with Endpoints News founder John Carroll to discuss the evolving role of CDMOs and what’s next for Catalent as it progresses with its shift from public to private ownership under its previously announced transaction with Novo Holdings.
Catalent Names Alessandro Maselli President and Chief Operating Officer. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and …
Catalent Pharma Solutions today announced that three of its experts will present at two upcoming conferences, Clinical Trial Supply (CTS) Europe and CTS New England.
